Evidence summaries for semaglutide across type 2 diabetes, obesity, cardiovascular outcomes, kidney outcomes, safety, dosing, and comparative therapy.
A prespecified secondary analysis of the STEP-HFpEF programme found that once-weekly semaglutide 2.4 mg lowered NT-proBNP and produced larger symptom gains in patients with higher baseline NT-proBNP. PICO summary and expert commentary.
A post hoc analysis of the SURPASS-2 phase 3 trial comparing tirzepatide and semaglutide on HOMA2 markers of beta-cell function and insulin sensitivity in type 2 diabetes. PICO summary and expert commentary.
Pooled analysis of the STEP-HFpEF and STEP-HFpEF DM trials of semaglutide 2.4 mg in obesity-related HFpEF, with PICO summary and expert commentary.
STEP-HFpEF DM: once-weekly semaglutide 2.4 mg improved symptoms, weight, and exercise capacity versus placebo in obese, diabetic patients with HFpEF. PICO summary and expert commentary.
Design and baseline characteristics of the phase 3 ESSENCE trial of weekly semaglutide 2.4 mg in 800 participants with biopsy-proven MASH and fibrosis stage 2 or 3, with no efficacy results reported yet. PICO summary and expert commentary.
A post hoc analysis of SUSTAIN 6 suggesting once-weekly semaglutide lowered new-onset diabetic kidney disease in type 2 diabetes. PICO summary and expert commentary.
A post hoc analysis of the SUSTAIN China trial found that the glycaemic efficacy of once-weekly semaglutide versus sitagliptin was consistent across most baseline subgroups. PICO summary and expert commentary.
A phase 1 crossover study of the IcoSema fixed-ratio combination of insulin icodec and semaglutide reports unchanged icodec exposure but a higher, earlier semaglutide peak versus separate injections. PICO summary and expert commentary.
Post hoc analysis of the STEP 1, 2, 3, and 5 trials finds semaglutide 2.4 mg did not increase depression or suicidal ideation versus placebo in people without major psychopathology. PICO summary and expert commentary.
Prespecified FLOW subgroup analysis testing whether semaglutide's kidney and cardiovascular benefits hold with or without baseline SGLT2 inhibitor use. PICO summary and expert commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
